PCSK9 Sponsors Still Face Challenges In Turning Around Dismal Launches
Executive Summary
After reporting yet another quarter of disappointing sales, Amgen and Sanofi/Regeneron look forward to better performance now that outcomes data are out, but payers may not be up for easing hurdles enough.
You may also be interested in...
Amgen Faces New ICER Roadblock To Repatha Reimbursement
The Institute for Clinical and Economic Review is lowering the value-based pricing benchmark for Amgen's PCSK9 inhibitor based on the results of the FOURIER cardiovascular outcomes trial – which was positive overall but did not show a reduction in CV mortality.
Sanofi Scouting For Cancer Deals, Diabetes Drugs Miss In 1Q
Sanofi is seeking asset deals to bulk up its oncology pipeline in 2017 – specifically, the big pharma is on the lookout for oncology compounds with potential in prostate cancer or breast cancer, the company highlighted during its first-quarter earnings call.
Amgen Hit By Enbrel 'Peculiarities' And Repatha Resistance
Amgen reported a surprising double-digit decline for Enbrel during the first quarter and sales for the cholesterol-lowering biologic Repatha showed that the PCSK9 inhibitor is not going to make up for the company's declining revenue any time soon – at least not while payers continue to block its use.